CLAYS

2.1 Classification of the substance or mixture

Depending on the handling and use (grinding, drying, bagging), airborne respirable dust may be generated. Dust contains respirable crystalline silica. Prolonged and or massive inhalation of respirable crystalline silica dust may cause lung fibrosis, commonly referred to as silicosis. Principal symptoms of silicosis are cough and breathlessness. Occupational exposure to respirable dust should be monitored and controlled. The product should be handled using methods and techniques that minimize or eliminate dust generation. The product contains less than 1% w/w RCS (respirable crystalline silica) as determined by the SWERF method. The respirable crystalline silica content can be measured using the “Size-Weighted Respirable Fraction – SWERF” method. All details about the SWERF method is available at www.crystallinesilica.eu. Regulation EC 1907/2006 (REACH) Not classified – is not hazardous substance. Regulation EC 1272/2008 (CLP) Doesn’t meet the criteria for classification. Directive 67/548/EEC It is not classified as a dangerous substance or mixture.

2.2 Label elements

Not applicable – not required.

2.3 Other hazards

Inorganic material of natural origin. The substance does not meet the criteria for PBT or vPvB substance. No other hazards identified. Clays are not known to have an adverse effect on the endocrine system in accordance with the criteria stated within Regulation (EU) 2017/2100 or Regulation (EU) 2018/605. The most severe adverse reactions to human health when using the material/preparation: None were observed. The most severe adverse reaction to the environment when using the material/preparation: None were observed.